1-2 of 2
Claire Nourry-Boulot
Close
Sort by
Journal Articles

Sabatolimab (MBG453) Combination Treatment Regimens for Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS): The MDS Studies in the Stimulus Immuno-Myeloid Clinical Trial Program

Amer M. Zeidan, Aref Al-Kali, Uma Borate, Thomas Cluzeau, Amy E. DeZern, Jordi Esteve, Aristoteles Giagounidis, Krissy Kobata, Roger Lyons, Uwe Platzbecker, David A. Sallman, Valeria Santini, Guillermo Sanz, Mikkael A. Sekeres, Andrew H. Wei, Zhijian Xiao, Marlies Van Hoef, Claire Nourry-Boulot, Islam Sadek, Bourras-Rezki Bengoudifa, Carolin Sachs, John Sabo, Guillermo Garcia-Manero
Journal: Blood
Blood (2021) 138 (Supplement 1): 4669.
https://doi.org/10.1182/blood-2021-145626
Published: 2021
Journal Articles

Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis

Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Giuseppe Saglio, MD, Richard A. Larson, MD, Hagop M. Kantarjian, MD, Dong-Wook Kim, Surapol Issaragrisil, MD, Philipp Le Coutre, MD, Gabriel Etienne, MD PhD, Carla Boquimpani, MD, Richard E. Clark, MA, MD MRCP, FRCPath, Viviane Dubruille, MD, Ian W. Flinn, MD PhD, Slawomira Kyrcz-Krzemien, MD PhD, Ewa Medras, MD, Maria Zanichelli, MD, Israel Bendit, MD PhD, Manu Sondhi, MD PhD, Ksenia Titorenko, MS, Claire Nourry-Boulot, PhD, Paola Aimone, MD, Andreas Hochhaus, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2924.
https://doi.org/10.1182/blood-2019-128761
Published: 2019